These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 31056970)

  • 1. Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases.
    Edwards CJ; Hercogová J; Albrand H; Amiot A
    Expert Opin Biol Ther; 2019 Oct; 19(10):1001-1014. PubMed ID: 31056970
    [No Abstract]   [Full Text] [Related]  

  • 2. Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody.
    Isaacs JD; Cutolo M; Keystone EC; Park W; Braun J
    J Intern Med; 2016 Jan; 279(1):41-59. PubMed ID: 26403380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unlocking the Value of Anti-TNF Biosimilars: Reducing Disease Burden and Improving Outcomes in Chronic Immune-Mediated Inflammatory Diseases: A Narrative Review.
    Rezk MF; Pieper B
    Adv Ther; 2020 Sep; 37(9):3732-3745. PubMed ID: 32740789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilars in IBD: Will it Benefit to Patients, Physicians or the Health Care System?
    Gonczi L; Ilias A; Kurti Z; Lakatos PL
    Curr Pharm Des; 2019; 25(1):13-18. PubMed ID: 30864504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress with infliximab biosimilars for inflammatory bowel disease.
    Kurti Z; Gonczi L; Lakatos PL
    Expert Opin Biol Ther; 2018 Jun; 18(6):633-640. PubMed ID: 29688797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilars in ulcerative colitis: When and for who?
    Ilias A; Gonczi L; Kurti Z; Lakatos PL
    Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars.
    Inotai A; Prins CPJ; Csanádi M; Vitezic D; Codreanu C; Kaló Z
    Expert Opin Biol Ther; 2017 Aug; 17(8):915-926. PubMed ID: 28650704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilars: A Multidisciplinary Perspective.
    Khraishi M; Stead D; Lukas M; Scotte F; Schmid H
    Clin Ther; 2016 May; 38(5):1238-49. PubMed ID: 26988243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars for the treatment of psoriasis.
    Puig L; López-Ferrer A
    Expert Opin Biol Ther; 2019 Oct; 19(10):993-1000. PubMed ID: 31237786
    [No Abstract]   [Full Text] [Related]  

  • 10. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
    Crespi-Lofton J; Skelton JB
    J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacovigilance and biosimilars: considerations, needs and challenges.
    Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
    Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Economic Impact of Biosimilars on Chronic Immune-Mediated Inflammatory Diseases.
    Pentek M; Zrubka Z; Gulacsi L
    Curr Pharm Des; 2017; 23(44):6770-6778. PubMed ID: 29189134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies.
    Numan S; Faccin F
    Adv Ther; 2018 Sep; 35(9):1295-1332. PubMed ID: 30084060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching to biosimilars in the treatment of rheumatic diseases.
    Yoo DH; Choe JY; Shim SC; Suh CH
    Expert Rev Clin Immunol; 2018 Jul; 14(7):557-571. PubMed ID: 29914272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.
    Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G
    Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Biosimilars in Patient Access to Therapeutic Antibodies for Immune Mediated Inflammatory Diseases.
    Chapman MA; Charles D; Loaiza-Bonilla A
    Curr Pharm Des; 2017; 23(44):6779-6783. PubMed ID: 29189136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab biosimilars for lymphoma in Europe.
    Jurczak W; Długosz Danecka M; Buske C
    Expert Opin Biol Ther; 2019 Oct; 19(10):1045-1056. PubMed ID: 31512535
    [No Abstract]   [Full Text] [Related]  

  • 18. Biosimilars of adalimumab: the upcoming challenge in IBD.
    Fiorino G; Gilardi D; Correale C; Furfaro F; Roda G; Loy L; Argollo M; Allocca M; Peyrin-Biroulet L; Danese S
    Expert Opin Biol Ther; 2019 Oct; 19(10):1023-1030. PubMed ID: 30601098
    [No Abstract]   [Full Text] [Related]  

  • 19. Are we ready to close the discussion on the interchangeability of biosimilars?
    Ebbers HC; Schellekens H
    Drug Discov Today; 2019 Oct; 24(10):1963-1967. PubMed ID: 31254488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world observational study of biosimilars in inflammatory arthritis treatment: a systematic literature review.
    Kim JW; Jung JY; Suh CH
    Expert Opin Biol Ther; 2021 Jan; 21(1):57-73. PubMed ID: 32808557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.